Last 12 months
Inside the activity.
7 purchase rows · 25 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 6 |
| Dec 2025 | 0 | 9 |
| Jan 2026 | 0 | 7 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 2 |
| Apr 2026 | 0 | 0 |
| May 2026 | 4 | 0 |
| Jun 2026 | 2 | 0 |
| Jul 2026 | 1 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 07, 2025 Filed Nov 11, 2025 01:09 UTC |
Brannan Stephen K.Director
|
GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.91 | $0.00 |
DisclosureSEC source: 0001708599-25-000128 · wk-form4_1762823384.xml · derivative · entry 1 Brannan Stephen K. · CIK 0001777631 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2035-11-07 F1 · derivative.exercise_date: The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| November 07, 2025 Filed Nov 11, 2025 01:05 UTC |
Bailey GregoryDirector
|
GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.91 | $0.00 |
DisclosureSEC source: 0001329505-25-000004 · wk-form4_1762823145.xml · derivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2035-11-07 F1 · derivative.exercise_date: The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| November 07, 2025 Filed Nov 11, 2025 00:57 UTC |
Venkatesan JayDirector
|
GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.91 | $0.00 |
DisclosureSEC source: 0001413350-25-000004 · wk-form4_1762822637.xml · derivative · entry 1 Venkatesan Jay · CIK 0001413350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2035-11-07 F1 · derivative.exercise_date: The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| November 07, 2025 Filed Nov 11, 2025 00:30 UTC |
WILSON KAREN JDirector
|
GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.91 | $0.00 |
DisclosureSEC source: 0001267490-25-000003 · wk-form4_1762821015.xml · derivative · entry 1 WILSON KAREN J · CIK 0001267490 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2035-11-07 F1 · derivative.exercise_date: The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| November 05, 2025 Filed Nov 6, 2025 21:40 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 3,398 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-25-000017 · wk-form4_1762465222.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 397,686 Underlying: Common Stock · 3,398 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| November 05, 2025 Filed Nov 6, 2025 21:40 UTC |
Moreadith RandallChief Scientific Officer
|
SaleCommon Stock | 3,398 | $4.24 | $14,407.52 |
DisclosureSEC source: 0001301120-25-000017 · wk-form4_1762465222.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.30 to $4.225. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| November 05, 2025 Filed Nov 6, 2025 21:40 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionCommon Stock | 3,398 | $0.06 | $203.88 |
DisclosureSEC source: 0001301120-25-000017 · wk-form4_1762465222.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,398 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 04, 2025 Filed Nov 5, 2025 20:29 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 3,102 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-25-000015 · wk-form4_1762374573.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 401,084 Underlying: Common Stock · 3,102 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| November 04, 2025 Filed Nov 5, 2025 20:29 UTC |
Moreadith RandallChief Scientific Officer
|
SaleCommon Stock | 3,102 | $4.40 | $13,634.22 |
DisclosureSEC source: 0001301120-25-000015 · wk-form4_1762374573.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.65 to $4.35. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| November 04, 2025 Filed Nov 5, 2025 20:29 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionCommon Stock | 3,102 | $0.06 | $186.12 |
DisclosureSEC source: 0001301120-25-000015 · wk-form4_1762374573.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,102 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 28, 2025 Filed Oct 29, 2025 21:04 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,551 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-25-000013 · wk-form4_1761771847.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 404,186 Underlying: Common Stock · 5,551 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| October 28, 2025 Filed Oct 29, 2025 21:04 UTC |
Moreadith RandallChief Scientific Officer
|
SaleCommon Stock | 5,551 | $4.96 | $27,541.29 |
DisclosureSEC source: 0001301120-25-000013 · wk-form4_1761771847.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.9625 to $4.95. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| October 28, 2025 Filed Oct 29, 2025 21:04 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionCommon Stock | 5,551 | $0.06 | $333.06 |
DisclosureSEC source: 0001301120-25-000013 · wk-form4_1761771847.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,551 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 27, 2025 Filed Oct 28, 2025 17:22 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 949 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-25-000011 · wk-form4_1761672139.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 409,737 Underlying: Common Stock · 949 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| October 27, 2025 Filed Oct 28, 2025 17:22 UTC |
Moreadith RandallChief Scientific Officer
|
SaleCommon Stock | 949 | $5.19 | $4,921.23 |
DisclosureSEC source: 0001301120-25-000011 · wk-form4_1761672139.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.25 to $5.10. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| October 27, 2025 Filed Oct 28, 2025 17:22 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionCommon Stock | 949 | $0.06 | $56.94 |
DisclosureSEC source: 0001301120-25-000011 · wk-form4_1761672139.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 949 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 20, 2025 Filed Oct 21, 2025 16:24 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-25-000009 · wk-form4_1761063888.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 410,686 Underlying: Common Stock · 6,500 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| October 20, 2025 Filed Oct 21, 2025 16:24 UTC |
Moreadith RandallChief Scientific Officer
|
SaleCommon Stock | 6,500 | $4.97 | $32,286.80 |
DisclosureSEC source: 0001301120-25-000009 · wk-form4_1761063888.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.02 to $4.88. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| October 20, 2025 Filed Oct 21, 2025 16:24 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionCommon Stock | 6,500 | $0.06 | $390.00 |
DisclosureSEC source: 0001301120-25-000009 · wk-form4_1761063888.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 13, 2025 Filed Oct 14, 2025 17:16 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 4,326 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-25-000007 · wk-form4_1760462176.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 417,186 Underlying: Common Stock · 4,326 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| October 13, 2025 Filed Oct 14, 2025 17:16 UTC |
Moreadith RandallChief Scientific Officer
|
SaleCommon Stock | 4,326 | $5.20 | $22,495.20 |
DisclosureSEC source: 0001301120-25-000007 · wk-form4_1760462176.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.25 to $5.18. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| October 13, 2025 Filed Oct 14, 2025 17:16 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionCommon Stock | 4,326 | $0.06 | $259.56 |
DisclosureSEC source: 0001301120-25-000007 · wk-form4_1760462176.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,326 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 26, 2025 Filed Aug 27, 2025 21:16 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 45,632 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-25-000005 · wk-form4_1756329396.xml · derivative · entry 6 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 421,512 Underlying: Common Stock · 45,632 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| August 26, 2025 Filed Aug 27, 2025 21:16 UTC |
Moreadith RandallChief Scientific Officer
|
SaleCommon Stock | 45,632 | $7.01 | $319,880.32 |
DisclosureSEC source: 0001301120-25-000005 · wk-form4_1756329396.xml · nonDerivative · entry 4 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F2 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.60 to $6.70. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| August 26, 2025 Filed Aug 27, 2025 21:16 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionCommon Stock | 45,632 | $0.06 | $2,737.92 |
DisclosureSEC source: 0001301120-25-000005 · wk-form4_1756329396.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,632 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 25, 2025 Filed Aug 27, 2025 21:16 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 2,042 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-25-000005 · wk-form4_1756329396.xml · derivative · entry 5 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 467,144 Underlying: Common Stock · 2,042 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| August 25, 2025 Filed Aug 27, 2025 21:16 UTC |
Moreadith RandallChief Scientific Officer
|
SaleCommon Stock | 2,042 | $5.65 | $11,537.30 |
DisclosureSEC source: 0001301120-25-000005 · wk-form4_1756329396.xml · nonDerivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.70 to $5.65. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| August 25, 2025 Filed Aug 27, 2025 21:16 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionCommon Stock | 2,042 | $0.06 | $122.52 |
DisclosureSEC source: 0001301120-25-000005 · wk-form4_1756329396.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,042 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 20, 2025 Filed Aug 20, 2025 21:13 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 2,077 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001708599-25-000097 · wk-form4_1755724400.xml · derivative · entry 6 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 469,186 Underlying: Common Stock · 2,077 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| August 20, 2025 Filed Aug 20, 2025 21:13 UTC |
Moreadith RandallChief Scientific Officer
|
SaleCommon Stock | 2,077 | $5.10 | $10,592.70 |
DisclosureSEC source: 0001708599-25-000097 · wk-form4_1755724400.xml · nonDerivative · entry 4 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Read SEC document |
| August 20, 2025 Filed Aug 20, 2025 21:13 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionCommon Stock | 2,077 | $0.06 | $124.62 |
DisclosureSEC source: 0001708599-25-000097 · wk-form4_1755724400.xml · nonDerivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,077 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 21:13 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 2,227 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001708599-25-000097 · wk-form4_1755724400.xml · derivative · entry 5 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 471,263 Underlying: Common Stock · 2,227 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 21:13 UTC |
Moreadith RandallChief Scientific Officer
|
SaleCommon Stock | 2,227 | $5.25 | $11,691.75 |
DisclosureSEC source: 0001708599-25-000097 · wk-form4_1755724400.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 21:13 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionCommon Stock | 2,227 | $0.06 | $133.62 |
DisclosureSEC source: 0001708599-25-000097 · wk-form4_1755724400.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,227 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 20:27 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,500 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001708599-25-000095 · wk-form4_1755203256.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 473,490 Underlying: Common Stock · 5,500 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 20:27 UTC |
Moreadith RandallChief Scientific Officer
|
SaleCommon Stock | 5,500 | $5.25 | $28,875.00 |
DisclosureSEC source: 0001708599-25-000095 · wk-form4_1755203256.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.36 to $5.13. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 20:27 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionCommon Stock | 5,500 | $0.06 | $330.00 |
DisclosureSEC source: 0001708599-25-000095 · wk-form4_1755203256.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 04, 2025 Filed Aug 6, 2025 21:22 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,500 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001708599-25-000085 · wk-form4_1754515343.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 478,990 Underlying: Common Stock · 5,500 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| August 04, 2025 Filed Aug 6, 2025 21:22 UTC |
Moreadith RandallChief Scientific Officer
|
SaleCommon Stock | 5,500 | $5.17 | $28,435.00 |
DisclosureSEC source: 0001708599-25-000085 · wk-form4_1754515343.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.35 to $5.13. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| August 04, 2025 Filed Aug 6, 2025 21:22 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionCommon Stock | 5,500 | $0.06 | $330.00 |
DisclosureSEC source: 0001708599-25-000085 · wk-form4_1754515343.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 29, 2025 Filed Jul 30, 2025 17:47 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 4,196 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001708599-25-000080 · wk-form4_1753897670.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 484,490 Underlying: Common Stock · 4,196 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| July 29, 2025 Filed Jul 30, 2025 17:47 UTC |
Moreadith RandallChief Scientific Officer
|
SaleCommon Stock | 4,196 | $6.50 | $27,274.00 |
DisclosureSEC source: 0001708599-25-000080 · wk-form4_1753897670.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Read SEC document |
| July 29, 2025 Filed Jul 30, 2025 17:47 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionCommon Stock | 4,196 | $0.06 | $251.76 |
DisclosureSEC source: 0001708599-25-000080 · wk-form4_1753897670.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 28, 2025 Filed Jul 29, 2025 10:10 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001708599-25-000078 · wk-form4_1753783796.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 488,686 Underlying: Common Stock · 6,500 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| July 28, 2025 Filed Jul 29, 2025 10:10 UTC |
Moreadith RandallChief Scientific Officer
|
SaleCommon Stock | 6,500 | $5.89 | $38,285.00 |
DisclosureSEC source: 0001708599-25-000078 · wk-form4_1753783796.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.02 to $5.60. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| July 28, 2025 Filed Jul 29, 2025 10:10 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionCommon Stock | 6,500 | $0.06 | $390.00 |
DisclosureSEC source: 0001708599-25-000078 · wk-form4_1753783796.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 21, 2025 Filed Jul 22, 2025 14:25 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001708599-25-000074 · wk-form4_1753194346.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 495,186 Underlying: Common Stock · 6,500 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| July 21, 2025 Filed Jul 22, 2025 14:25 UTC |
Moreadith RandallChief Scientific Officer
|
SaleCommon Stock | 6,500 | $5.34 | $34,710.00 |
DisclosureSEC source: 0001708599-25-000074 · wk-form4_1753194346.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.31 to $5.40. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| July 21, 2025 Filed Jul 22, 2025 14:25 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionCommon Stock | 6,500 | $0.06 | $390.00 |
DisclosureSEC source: 0001708599-25-000074 · wk-form4_1753194346.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 14, 2025 Filed Jul 17, 2025 14:40 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001708599-25-000071 · wk-form4_1752763244.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 501,686 Underlying: Common Stock · 6,500 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.